Back to Search Start Over

In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare CandidaSpecies as Determined by CLSI Broth Microdilution Methods

Authors :
Diekema, D. J.
Messer, S. A.
Boyken, L. B.
Hollis, R. J.
Kroeger, J.
Tendolkar, S.
Pfaller, M. A.
Source :
Journal of Clinical Microbiology; October 2009, Vol. 47 Issue: 10 p3170-3177, 8p
Publication Year :
2009

Abstract

ABSTRACTFive Candidaspecies (C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei) account for over 95% of invasive candidiasis cases. Some less common Candidaspecies have emerged as causes of nosocomial candidiasis, but there is little information about their in vitro susceptibilities to antifungals. We determined the in vitro activities of fluconazole, voriconazole, posaconazole, amphotericin B, anidulafungin, caspofungin, and micafungin against invasive, unique patient isolates of Candidacollected from 100 centers worldwide between January 2001 and December 2007. Antifungal susceptibility testing was performed by the CLSI M27-A3 method. CLSI breakpoints for susceptibility were used for fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin, while a provisional susceptibility breakpoint of =1 µg/ml was used for amphotericin and posaconazole. Of 14,007 Candidaisolates tested, 658 (4.7%) were among the less common species. Against all 658 isolates combined, the activity of each agent, expressed as the MIC50/MIC90ratio (and the percentage of susceptible isolates) was as follows: fluconazole, 1/4 (94.8%); voriconazole, 0.03/0.12 (98.6%); posaconazole, 0.12/0.5 (95.9%); amphotericin, 0.5/2 (88.3%); anidulafungin, 0.5/2 (97.4%); caspofungin, 0.12/0.5 (98.0%); and micafungin, 0.25/1 (99.2%). Among the isolates not susceptible to one or more of the echinocandins, most (68%) were C. guilliermondii. All isolates of the less common species within the C. parapsilosiscomplex (C. orthopsilosisand C. metapsilosis) were susceptible to voriconazole, posaconazole, anidulafungin, caspofungin, and micafungin. Over 95% of clinical isolates of the rare Candidaspecies were susceptible to the available antifungals. However, activity did vary by drug-species combination, with some species (e.g., C. rugosaand C. guilliermondii) demonstrating reduced susceptibilities to commonly used agents such as fluconazole and echinocandins.

Details

Language :
English
ISSN :
00951137 and 1098660X
Volume :
47
Issue :
10
Database :
Supplemental Index
Journal :
Journal of Clinical Microbiology
Publication Type :
Periodical
Accession number :
ejs57786385
Full Text :
https://doi.org/10.1128/JCM.00942-09